ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Links shared publicly online about this topic.

1,314
total visits

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

View full resource at news-medical.net

Tags: Cholesterol, Diabetes, Type 2 Diabetes, Obesity